HMGB1 in sepsis

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 9, 2003, Pages 577-584

  Andersson, Ulf ^a   Tracey, Kevin J ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Northwell Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; NUCLEAR PROTEIN;

ARTHRITIS; CELL DAMAGE; CELL DEATH; DRUG TARGETING; ENDOTHELIUM CELL; ENDOTOXEMIA; EXTRACELLULAR SPACE; GENETIC TRANSCRIPTION; IMMUNOREGULATION; IN VIVO STUDY; INFLAMMATION; LETHALITY; MACROPHAGE; MONOCYTE; NERVE CELL; NONHUMAN; NUCLEOSOME; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANIMALS; HMGB1 PROTEIN; HUMANS; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0242288518     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540310016286     Document Type: Review

References (39)

1. Goodwin GH, Johns EW. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins. Methods Cell Biol 1977; 16: 257-67.
2. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2000; 26: 152-3.
3. Muller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J 2001; 20: 4337-40.
4. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-51.
5. Czura CJ, Tracey KJ. Targeting high mobility group box 1 as a late-acting mediator of inflammation. Crit Care Med 2003; 31: S46-50.
6. Yang H, Wang H, Czura CJ, Tracey KJ. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res 2002; 8: 469-72.
7. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002; 72: 1084-91.
8. Landsman D, Bustin M. A signature for the HMG-1 box DNA-binding proteins. Bioassays 1993; 15: 539-46.
9. Ferrari S, Finelli R, Rocchi M, Bianchi ME. The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics 1996; 35: 367-71.
10. Calogero S, Grassi F, Aguzzi A, Voigtlander T, Ferrier P, Ferrari S, Bianchi ME. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet 1999; 22: 276-80.
11. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 2003; 9: 37-45.
12. Yang H, Wang H, Tracey KJ. HMG-1 rediscovered as a cytokine. Shock 2001; 15: 247-53.
13. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo CG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
14. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001.
15. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003; 170: 3890-7.
16. Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost 2000; 84: 1087-94.
17. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5.
18. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-70.
19. Bucciarelli LG, Wendt T, Rong L, Lalla LE, Hofmann MA, Goova MT, et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002; 59: 1117-28.
20. Park JS, Arcaroli J, Yum HK, Yang H, Wang H, Yang KY, et al. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol 2003; 284: C870-9.
21. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002; 123: 790-802.
22. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F, et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J Cell Biol 2001; 152: 1197-206.
23. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-60.
24. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-61.
25. Huttunen HJ, Kuja-Panula J, Sorci G, Agneletti AL, Donato R, Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000; 275: 40096-105.
26. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-60.
27. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
28. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 2950-4.
29. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
30. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27: 1230-51.
31. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris H, et al. Reversing established sepsis with antagonists of endogenous HMGB1. Proc Natl Acad Sci USA 2003 in press.
32. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-70.
33. Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148: 2724-30.
34. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99: 12351-6.
35. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Wang H, Ulloa L, et al. HMGB1 - a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002; 46: 2598-603.
36. Pullerits R, Jonsson I-M, Verdrengh M, Bokarewa M, Andersson U, Erlandsson Harris H, Tarkowski A. HMGB1 - a DNA-binding cytokine induces arthritis. Arthritis Rheum 2003; 48: 1693-700.
37. Kokkola R, Sundberg E, Aveberger AC, Palmblad K, Yang H, Tracey KJ, et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48: 2052-8.
38. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48: 971-81.
39. Ulloa L, Batliwalla FM, Andersson U, Gregersen PK, Tracey KJ. HMGB1 as a nuclear protein, cytokine and potential therapeutic target in arthritis. Arthritis Rheum 2003; 48: 876-81.